Not provided
Not provided
Not provided
Not provided
Very slow accrual because sites have few open colorectal surgery
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a multi-centre study to take place in approximately 3 centers in Seoul, South Korea. The study will be carried out as a prospective, randomized, controlled, multicenter, clinical trial in patients undergoing colorectal surgery. The purpose of this study is to determine if an enhanced recovery strategy paying close attention to the type and amount of fluid given during the surgery with proper monitoring combined with a comprehensive perioperative pain management will have a better post-operative outcome compared to institutional standard of care (SOC), in patients undergoing surgery of the colon. One of the fluids used, Volulyte®, is an intravenous solution used to treat low blood volume. The Volulyte® solution being used in the study and the monitor used are approved by the Korean Food and Drug Administration
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Standard of Care (SOC) | Other | Intraoperative fluid management includes Volulyte® (6% hydroxyethyl starch {HES} 130/0.4 in balanced solution) as the only colloid solution to be used, the daily dosage of Volulyte® is restricted to 50 ml/kg. Intraoperative anesthesia and postoperative analgesia will follow the established practice of the individual institution. |
|
| Enhanced Recovery Strategy (ERS) group | Active Comparator | GDFT regimen using Volulyte® (6% HES 130/0.4 in balanced solution) during surgery. The daily dosage of Volulyte® is restricted to 50 ml/kg. Combined epidural-general anesthesia (CEGA) will be used intraoperatively and patient-controlled epidural analgesia (PCEA) will be used postoperatively in a multimodal analgesic regimen. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Combined epidural-general anesthesia (CEGA) | Other | Combined epidural-general anesthesia (CEGA) will be used intraoperatively and patient-controlled epidural analgesia (PCEA) will be used postoperatively in a multimodal analgesic regimen. |
| Measure | Description | Time Frame |
|---|---|---|
| Postoperative Outcome | Postoperative outcome is defined as the number of patients who develop at least one postoperative complication during their hospital stay | From Day 1 after surgery and duration of hospital stay (approximately 6 days after surgery) |
| Measure | Description | Time Frame |
|---|---|---|
| Postoperative outcome for each patient at postoperative day (POD) 30 | Postoperative outcome for each patient at postoperative day (POD) 30 is defined as whether the patient encountered at least one postoperative complication up to POD 30 | From Hospital Discharge (approximately 6 days after surgery), up to 4 weeks after day of surgery |
| Measure | Description | Time Frame |
|---|---|---|
| Time of first bowel movement | After surgery until occurence of first bowel movement during hospital stay (approximately 6 days after surgery) | |
| Time to tolerating liquid intake | After surgery until subject is able to tolerate oral fluids during hospital stay(approximately 6 days after surgery) |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Tong J Gan, MD, MHS | Duke University | Principal Investigator |
| Yang-Sik Shin, MD | Shinchon Severance Hospital | Principal Investigator |
| Duk-Kyung Kim, MD PhD | Samsung Medical Center | Principal Investigator |
| Gyu-Jeong Noh, MD PhD | Asan Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Samsung Medical Center | Gangnam-Gu | Seoul | 135-710 | South Korea | ||
| Yonsei University College of Medicine |
Not provided
| ID | Term |
|---|---|
| D006895 | Hydroxyethyl Starch Derivatives |
| ID | Term |
|---|---|
| D013213 | Starch |
| D004040 | Dietary Carbohydrates |
| D002241 | Carbohydrates |
| D005936 | Glucans |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Volulyte® (6% HES 130/0.4 in balanced solution) | Drug | For the SOC Group: Intraoperative fluid management includes Volulyte® (6% HES 130/0.4 in balanced solution) as the only colloid solution to be used, the daily dosage of Volulyte® is restricted to 50 ml/kg. For the ERS Group: GDFT regimen will be utilized using Volulyte® (6% HES 130/0.4 in balanced solution) during surgery. The daily dosage of Volulyte® is restricted to 50 ml/kg. |
|
| Patient-Controlled Epidural Analgesia (PCEA) | Other | For the ERS Group, patient-controlled epidural analgesia (PCEA) will be used postoperatively in a multimodal analgesic regimen. |
|
| Number of postoperative complications per group |
Number of postoperative complications per group evaluated postoperatively from date of surgery, each hospital day, (post-operative days 1 through 5), at discharge from the hospital until 30 days from day of surgery. |
| Participants will be followed for the duration of hospital stay (approximately 6 days after surgery), and until 4 weeks from day of surgery |
| Time to "clinically fit for discharge from hospital" | Time to "clinically fit for discharge from hospital" when defined discharge criteria are met (evaluation starts from POD 4 at 10 am each day till discharge). | From 4 days after surgery to Hospital discharge (approximately 6 days after surgery) |
| Change in Postoperative pain | Postoperative pain at 1h, 2 h, 6 h, 24 h, and post-operative days 1 through 5, and at discharge (evaluated with a verbal rating scale (VRS), 0 = no pain, 10 = worst possible pain) until discharge. Pain assessment is performed at rest and during activity (cough). | 1h, 2 h, 6 h, 24 h post-surgery, and post-operative days 1 through 5, and at discharge |
| change in incidence of nausea and vomiting | The incidence of nausea and vomiting at 1h, 2 h, 24 h, and post-operative days 2 through 5, and at discharge from the hospital. | 1h, 2 h, 24 h post-surgery, and post-operative days 2 through 5, and at discharge from the hospital (approximately 6 days after surgery) |
| Time to tolerating solid intake. | After surgery until subject is able to tolerate solid oral intake during hospital stay (approximately 6 days after surgery) |
| Postoperative recovery score (QoR-15) | Recovery Scores will be taken at hospital stay (POD 1 to POD 5, Hospital Discharge) and will be repeated at POD 30 | For duration of hospital stay (approximately 6 days after surgery), and 4 weeks after the surgery |
| 6 min Walk Test | If tolerated, individual walks without physical assistance for 6 minutes and the distance is measured. this test will be done at hospital stay (POD 1 to POD 5, Hospital Discharge) and will be repeated at POD 30 | For duration of hospital stay (approximately 6 days after surgery), and 4 weeks after the surgery |
| Seodaemun-gu |
| Seoul |
| South Korea |
| Asan Medical Center | Songpa-gu | Seoul | 138-736 | South Korea |
| D011134 |
| Polysaccharides |